Pharmacy Times – November 2014


Drug Interactions: Insights and Observations


Codeine Drug Interactions


John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD





1. Sanfilippo G. Contributo sperimententeale aliĠipotesi della smetilazione della codeine nella-organismo. I. Influence della dose sullĠassuefazione alla codeina. II. Assuefazione alla codeina attenuta con somministrazione prolungata di morfina Boll Soc Ital Biol Sper 1948:24:723-26.

2. Sanfilippo G. Experimental contribution to the hypothesis of demethylation of codeine in the organism. III. Habituation to morphine obtained by prolonged administration of codeine. Boll Soc Ital Biol Sper 19:29:1761-3.

3. Sanfilippo G. The demethylation of codeine in vivio. Arch Ital Sci Farmacol. 1953;3:357-66.

4. Yue QY, et al. Codeine O-demthylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989;28:639-645.

5. Desmeules J, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol. 1991;41:23-6.

6. Poulsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol. 1996;51:289-95.

7. Eckhardt K, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determine differences in morphine formation. Pain. 1998;76:27-33.

8. Bertilsson L et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-80.

9. Johansson I, et al. Interhited amplification of an active gene in the cytochrome P450 2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci 1993:90:111825-9.

10. Dalen P, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997:19:543-44.

11. Gasche Y et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827-31.

12. Koren G et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704.

13. Ciszkowski C, Madadi P. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361:827-8.

14. Caraco Y, et al. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeineĠs respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther. 1997;281:330-336.

15. Meissner K, et al. Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. Anesthesiology. 2013:119:941-953.

16. Tzvetkov MV, et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics. Biochem Pharmacol. 2013;86:666-678.

17. Crews KR, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95:376-382.